ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults

Inclusion Criteria

• •Able to read, understand, and sign an informed consent form before any study procedures
• •Male or female adults aged 18 to 75 years with a physician diagnosis of moderate to severe asthma for at least 12 months
• •Receiving stable treatment with an inhaled corticosteroid (ICS) plus a long-acting beta₂-agonist (LABA) for at least 2 months before screening
• •Pre-bronchodilator FEV₁ between 50% and 80% of predicted normal at screening and baseline
• •Demonstrated bronchodilator reversibility
• •ACQ-5 score ≥1.25 to ≤3.0 at screening and baseline
• •History of at least one asthma exacerbation in the past 12 months requiring systemic corticosteroids or hospitalization/emergency care